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 The advent of biologic agents revolutionized the 
treatment of psoriasis and psoriatic arthritis, providing 
treatment option to many patients previously unresponsive 
to phototherapy and conventional systemic treatments.1 
The unprecedented impact on these patients has been 
major, with significant overall sustained positive effects on 
disease burden, quality of life issues as well on systemic 
inflammation and comorbidities. Likewise, their benefit/risk 
ratio has proved excellent provided that the recommended 
pre-inclusion measures and follow-up are thoroughly 
respected.2 However, these therapies impose a heavy 
burden on the healthcare system due to their high costs. In 
2013, a total of 27% of pharmaceutical sales were biological 
agents, mainly for cancer and immune-mediated diseases, 
and in 2015, two of the five top selling therapies were TNF-α 
inhibitors, adalimumab and etanercept.3
 Biosimilars, defined by EMA as a ‘biological medicinal 
product that contains a version of the active substance of 
an already authorised original biological medicinal product 
(reference product)’4 are an attractive strategy to reduce 
therapy-related costs and increase patient access to 
highly effective drugs. As innovator biologics used to treat 
psoriasis and psoriatic arthritis are losing patent protection, 
there are several biosimilars versions of those agents being 
developed.5 Biosimilars must be viewed differently than 
generic copies of chemically synthetized drugs, due to their 
high molecular weight, complex molecular structure and 
post-transcriptional modifications, such as glycosylation, 
methylation, oxidation and deamination, that impact on 
tertiary and quaternary structure. In order to be approved 
by regulatory agencies, biosimilars must prove to be 
highly structurally analogous to the reference drug and to 
be highly similar in terms of quality, safety, efficacy and 
immunogenicity profile to the originator agent.6 Thus, as 
their name indicates, biosimilars are highly similar to the 
originator product, but due to differences in manufacturing 
processes they are not identical.
 Biosimilars may cost 25% - 30% less than the original 
agents, as the manufacturing process and development 
costs are considerably lower. Moreover, through market 
pressure, biosimilars may also reduce the costs of the 
original biopharmaceuticals. Thus, biosimilars are expected 
to reduce health care costs and to increase patient access 
to biologic agents, contributing to the financial sustainability 
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of health care systems, as it has been observed in oncology 
and endocrinology setting. However, due to considerable 
differences between countries’ health systems, there 
may be high variability in budget impact saving between 
countries.
 Although developing a biosimilar with an efficacy 
and safety profile similar to the reference product can be 
challenging, due to the complex molecular structure and 
complicated manufacturing process, currently, there is a high 
regulatory bar for biosimilar products and their approval is a 
highly regulated procedure. EMA first developed guidelines 
for approval of biosimilars in 20057 that were later updated 
and in 2013 a specific guideline for monoclonal antibodies 
was adopted.8 According to these guidelines, to demonstrate 
biosimilarity and gain regulatory approval for a biosimilar, 
EMA (and also other regulatory agencies, like FDA) require 
a pharmacokinetic/pharmacodynamics study in humans 
and at least one randomized clinical trial to demonstrate 
equivalent efficacy, immunogenicity and similar safety 
profile as compared to its reference product8. Nevertheless, 
the main safety issues concerning biosimilars are related to 
immunogenicity, hypersensitive reactions and an increased 
risk of other adverse effects.
 There are several debatable considerations related to 
biosimilars, mainly extrapolation, interchangeability and 
automatic substitution, naming and traceability and long-
term safety.
 Extrapolation means that a clinical indication of a 
reference drug may be granted to the biosimilar without the 
requirement for clinical studies to support that indication. 
It is basically supported by the assumption that the two 
agents have similar molecular structure, mechanisms 
of action and equivalent clinical efficacy and safety. The 
possibility of gaining approval for all indications held by the 
reference product based on less extensive nonclinical data, 
and minimal clinical data in only a subset of indications 
is a main driver of biosimilar cost reduction. EMA allows 
extrapolation of indications, mentioning that efficacy and 
safety data for a biosimilar agent could be generalized from 
one indication to another ‘if the reference product acts by 
the same mechanism in each disease state’.9
 Untill this date, two biosimilars have been approved 
for treatment of psoriasis and psoriatic arthritis, CT-P13 
(infliximab biosimilar – Remsima™, Celltron, Inc and 
Inflectra™, Hospira, Inc) and SB4 (etanercept biosimilar 
- Benapali™, Samsung Bioepis Co.), based in studies in 
rheumatoid arthritis (CT-P13 and SB4) and ankylosing 
spondylitis (CT-P13).10,11 The main issue raised by the 
concept of extrapolation of indications is in what specific 
inflammatory disease or diseases should a biosimilar agent 
be studied in order to provide adequate information for 
extrapolation of indications. In fact, although the therapeutic 
target (TNF-α), is implicated in the pathophysiology of several 
immune-mediated diseases, their clinical manifestations 
are distinct, and their mechanisms of action, sites of 
action, pharmacokinetics, dose, concomitant medications, 
comorbidities, immunogenicity risk and safety profile may 
widely differ. Moreover, there is some serious and relevant 
debate on whether rheumatoid arthritis is the best model 
(most sensitive) to evaluate biosimilarity and to provide data 
for extrapolation, due to different dose regimen, concomitant 
use of methotrexate and different pathogenesis.12 However, 
many of the concerns raised regarding extrapolation may be 
hypothetical, and likely not problematic in the long term. In 
fact, there is increasing evidence that the use of Infliximab 
biosimilar (CT-P13), approved for all the originator’s 
indications based on clinical trials conducted in patients 
with rheumatoid arthritis and ankylosing spondylitis, is also 
effective and safe in inflammatory bowel disease.13-15 
 Nevertheless, dermatologists will probably be more 
confident and less reluctant using biosimilars that have 
been previously studied in psoriasis patients, and currently, 
several biosimilars of adalimumab and etanercept are being 
evaluated in psoriasis patients.5 
 Regarding switching a reference product by a biosimilar, 
or vice-versa, there are several relevant considerations for 
clinical practice. Drug switching refers to the transitioning 
from one biologic agent to another (reference to biosimilar 
and vice-versa); automatic substitution refers to replacement 
of one biologic agent with another by the pharmacist without 
the approval or knowledge of the prescribing physician; 
interchangeability or the condition of an ‘interchangeable 
biological’ has been defined by the FDA as a product that ‘‘in 
addition to meeting the biosimilarity standard, is expected to 
produce the same clinical result as the reference product in 
any given patient, and for a product that is given to a patient 
more than once, the risk in terms of safety and effectiveness 
of alternating or switching between the interchangeable and 
the reference product is not greater than the risk of using the 
reference product without alternating or switching’.16 In order 
to considered an interchangeable biological, the agent must 
meet specific criteria that are currently under consideration 
by the FDA, for instance, it may be necessary to previously 
perform crossover and repeated switching studies. Once a 
biosimilar has proved to be interchangeable, a pharmacist 
might replace the reference product, without the intervention 
of the physician who prescribed the reference product, in 
other words, automatic substitution. However, EMA has no 
addressed the issues of interchangeability, switchability and 
automatic substitution of biosimilar and reference products, 
leaving the corresponding decisions in the hands of the 
health authorities of each member state of the European 
Union.17
 There is not clear evidence supporting switching and 
interchangeability. Currently, there are some studies 
accessing real-world data about switching, for example the 
Norwegian NOR-SWITCH study, that evaluates, for a period 
of 12 months, maintenance of efficacy as well as safety 
following switching from reference to biosimilar infliximab. 
However, it should not be forgotten that this is a ‘one switch 
study’ that may only demonstrate no loss of efficacy nor 
increase risk for this biosimilar in particular and for just one 
switch. Switching, or even interchangeability will only be 
accepted with robust evidence, probably through multiple 
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switching studies conducted during the development of 
the biosimilar. As an example, the etanercept biosimilar 
GP2015 is being studied in a phase III crossover trial, with 
more than one switch, in psoriasis.18 
 Due to the abbreviated clinical development programme 
of biosimilar agents, which is less able to identify small 
safety risks as compared with the development of 
reference products, post-marketing pharmacovigilance is 
of critical importance for assessment of long-term safety of 
biosimilars. EMA has designed a complete post-marketing 
pharmacovigilance program for biosimilars which includes a 
post-marketing safety study as well as the implementation of 
a risk management plan, that included spontaneous reports 
of potential side effects related to use of a biosimilar after 
these are reported by patients or healthcare professionals, 
creation of periodic safety update reports and promotion of 
post-authorization safety studies.19
 Another important aspect concerns naming of biosimilars 
as it may significantly affect both affect traceability and 
pharmacovigilance. There is no established international 
standardized system of nomenclature for biosimilars, which 
is currently determined on a national level. EMA advises 
that commercial name, appearance and packing should 
differ.17 
 In February 2016 the Portuguese National Authority of 
Medicines and Health Products (INFARMED, IP) released 
a recommendation document about the use of biosimilars. 
In this document, it is clearly recommended the use of 
biosimilars as it is associated with reduced therapy-related 
costs and increase patients’ access to biological therapies. 
Moreover, it is recommended that therapeutic agents with 
approved biosimilars should be the first choice of treatment. 
For naïve patients, it is recommended as first option the 
use of biosimilars (if it is more economic than the 
reference agent) at all the approved clinical indications 
the reference product has, thus showing no concerns 
regarding the extrapolation of indications. The importance 
of pharmacovigilance and traceability is highlighted with 
recommendations regarding these aspects. Finally, no clear 
position is stated regarding switching between reference 
and biosimilar agents. Some concerns are expressed 
regarding safety issues, specifically immunogenicity, and it is 
recommended that any decision should be taken cautiously 
always involving the clinicians that are responsible for 
patients’ care.20 
Portuguese position on the use of biosimilars in 
psoriasis
 • Biosimilars are welcomed in the treatment of psoriasis 
and psoriatic arthritis if they are able to reduce medical 
costs and increase access to biologic therapy, improving 
patient’s care and providing saving and efficiency for health 
care systems, therefore releasing resources for others 
important aspects of health care.
 • In patients’ best interest, the development of bio-
similars must be critically evaluated. Medical and 
immunological considerations, including high-quality 
evidence of bioequivalence, quality, efficacy and safety of 
each developed biosimilar should always take priority over 
any economic or financial benefit.
 • Many of the concerns raised regarding extrapolation 
may in the future prove to have no practical impact. 
However, since several biosimilars are being evaluated in 
psoriasis patients, these agents should be chosen to treat 
psoriasis patients instead of biosimilars studied in other 
conditions.
 • There is no evidence to support switching between a 
reference biologic agent and a biosimilar and vice-versa, so 
this should not be recommended. 
 • Any decision to substitute a biosimilar product should 
only be made by the prescribing physician and automatic 
substitution is strongly objected. Moreover, patients should 
be kept informed about their treatment agent, and should 
not be transitioned for other agent without their knowledge 
and informed consent.  
 • Biosimilars should be subjected to the same standards 
of pharmacovigilance as do the reference biological agents. 
Post-marketing surveillance, mainly through national 
registers, is crucial to permanently assess safety and 
increase confidence in the use of biosimilars.
 • In the absence of established international standardi-
zed system of nomenclature for biosimilars, careful 
biosimilar identification and recording (including the brand 
name and batch number) is of utmost importance for safety 
reasons and for securing traceability. 
 • Biosimilars should not prevent or delay access to 
therapeutic innovation, and physicians must retain full 
authority concerning the decision of which therapeutic 
agent is selected to treat their patients.
 • These opinions may change with time. Daily clinical 
experience and new data will be of critical importance.
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